Literature DB >> 28029317

Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.

Marianne J Rutten1, Hannah S van Meurs1, Roelien van de Vrie1, Katja N Gaarenstroom1, Christiana A Naaktgeboren1, Toon van Gorp1, Henk G Ter Brugge1, Ward Hofhuis1, Henk W R Schreuder1, Henriette J G Arts1, Petra L M Zusterzeel1, Johanna M A Pijnenborg1, Maarten van Haaften1, Guus Fons1, Mirjam J A Engelen1, Erik A Boss1, M Caroline Vos1, Kees G Gerestein1, Eltjo M J Schutter1, Brent C Opmeer1, Anje M Spijkerboer1, Patrick M M Bossuyt1, Ben Willem Mol1, Gemma G Kenter1, Marrije R Buist1.   

Abstract

Purpose To investigate whether initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with advanced-stage ovarian cancer in whom > 1 cm of residual disease will be left after PCS. Patients and Methods This multicenter, randomized controlled trial was undertaken within eight gynecologic cancer centers in the Netherlands. Patients with suspected advanced-stage ovarian cancer who qualified for PCS were eligible. Participating patients were randomly assigned to either laparoscopy or PCS. Laparoscopy was used to guide selection of primary treatment: either primary surgery or neoadjuvant chemotherapy followed by interval surgery. The primary outcome was futile laparotomy, defined as a PCS with residual disease of > 1 cm. Primary analyses were performed according to the intention-to-treat principle. Results Between May 2011 and February 2015, 201 participants were included, of whom 102 were assigned to diagnostic laparoscopy and 99 to primary surgery. In the laparoscopy group, 63 (62%) of 102 patients underwent PCS versus 93 (94%) of 99 patients in the primary surgery group. Futile laparotomy occurred in 10 (10%) of 102 patients in the laparoscopy group versus 39 (39%) of 99 patients in the primary surgery group (relative risk, 0.25; 95% CI, 0.13 to 0.47; P < .001). In the laparoscopy group, three (3%) of 102 patients underwent both primary and interval surgery compared with 28 (28%) of 99 patients in the primary surgery group ( P < .001). Conclusion Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer. In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to < 1 cm of residual disease seems feasible, to proceed with PCS.

Entities:  

Mesh:

Year:  2016        PMID: 28029317     DOI: 10.1200/JCO.2016.69.2962

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Authors:  Martina Aida Angeles; Federico Migliorelli; Mathilde Del; Carlos Martínez-Gómez; Manon Daix; Sarah Bétrian; Erwan Gabiache; Gisèle Balagué; Sophie Leclerc; Eliane Mery; Laurence Gladieff; Gwénaël Ferron; Alejandra Martinez
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

2.  Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Authors:  Nicole D Fleming; Alpa M Nick; Robert L Coleman; Shannon N Westin; Pedro T Ramirez; Pamela T Soliman; Bryan Fellman; Larissa A Meyer; Kathleen M Schmeler; Karen H Lu; Anil K Sood
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

3.  Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.

Authors:  Stephanie Cham; Ling Chen; Caryn M St Clair; June Y Hou; Ana I Tergas; Alexander Melamed; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2019-02-13       Impact factor: 8.661

Review 4.  Prediction of optimal debulking surgery in ovarian cancer.

Authors:  Yong Jung Song
Journal:  Gland Surg       Date:  2021-03

5.  Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Authors:  Krishnansu S Tewari; Robert A Burger; Danielle Enserro; Barbara M Norquist; Elizabeth M Swisher; Mark F Brady; Michael A Bookman; Gini F Fleming; Helen Huang; Howard D Homesley; Jeffrey M Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Chenglin Ye; Carlos Bais; Leslie M Randall; John K Chan; J Stuart Ferriss; Robert L Coleman; Carol Aghajanian; Thomas J Herzog; Philip J DiSaia; Larry J Copeland; Robert S Mannel; Michael J Birrer; Bradley J Monk
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 44.544

6.  A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.

Authors:  Alli M Straubhar; Olga T Filippova; Renee A Cowan; Yulia Lakhman; Debra M Sarasohn; Ines Nikolovski; Jean M Torrisi; Weining Ma; Nadeem R Abu-Rustum; Ginger J Gardner; Yukio Sonoda; Oliver Zivanovic; Dennis S Chi; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2020-06-06       Impact factor: 5.482

7.  Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Authors:  Jean M Hansen; Anil K Sood; Robert L Coleman; Shannon N Westin; Pamela T Soliman; Pedro T Ramirez; Bryan M Fellman; Kathleen M Schmeler; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2018-10-23       Impact factor: 5.482

8.  Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.

Authors:  Ross F Harrison; Scott B Cantor; Charlotte C Sun; Mariana Villanueva; Shannon N Westin; Nicole D Fleming; Iakovos Toumazis; Anil K Sood; Karen H Lu; Larissa A Meyer
Journal:  Gynecol Oncol       Date:  2021-01-31       Impact factor: 5.482

9.  Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.

Authors:  Zheng Feng; Hao Wen; Ruimin Li; Shuai Liu; Yi Fu; Xiaojun Chen; Rui Bi; Xingzhu Ju; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

10.  Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Shannon N Westin; Larissa A Meyer; Aaron Shafer; Jose Alejandro Rauh-Hain; Michaela Onstad; Lauren Cobb; Michael Bevers; Bryan M Fellman; Jennifer Burzawa; Priya Bhosale; Behrouz Zand; Amir Jazaeri; Charles Levenback; Robert L Coleman; Pamela T Soliman; Anil K Sood
Journal:  Int J Gynecol Cancer       Date:  2020-11-05       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.